Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
Public ClinicalTrials.gov record NCT03345784. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination With Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I trial studies the side effects and best dose of adavosertib when given together with external beam radiation therapy and cisplatin in treating patients with cervical, vaginal, or uterine cancer. Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. External beam radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving adavosertib, external beam radiation therapy, and cisplatin may work better in treating patients with cervical, vaginal, or uterine cancer.
Study identification
- NCT ID
- NCT03345784
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 10 participants
Conditions and interventions
Conditions
- Cervical Carcinoma
- Endometrioid Adenocarcinoma
- Malignant Female Reproductive System Neoplasm
- Recurrent Cervical Carcinoma
- Stage I Uterine Corpus Cancer AJCC v7
- Stage I Vaginal Cancer AJCC v6 and v7
- Stage IA Uterine Corpus Cancer AJCC v7
- Stage IB Cervical Cancer AJCC v6 and v7
- Stage IB Uterine Corpus Cancer AJCC v7
- Stage IB2 Cervical Cancer AJCC v6 and v7
- Stage II Cervical Cancer AJCC v7
- Stage II Uterine Corpus Cancer AJCC v7
- Stage II Vaginal Cancer AJCC v6 and v7
- Stage IIA Cervical Cancer AJCC v7
- Stage IIB Cervical Cancer AJCC v6 and v7
- Stage III Cervical Cancer AJCC v6 and v7
- Stage III Uterine Corpus Cancer AJCC v7
- Stage III Vaginal Cancer AJCC v6 and v7
- Stage IIIA Cervical Cancer AJCC v6 and v7
- Stage IIIA Uterine Corpus Cancer AJCC v7
- Stage IIIB Cervical Cancer AJCC v6 and v7
- Stage IIIB Uterine Corpus Cancer AJCC v7
- Stage IIIC Uterine Corpus Cancer AJCC v7
- Vaginal Carcinoma
Interventions
- Adavosertib Drug
- Cisplatin Drug
- External Beam Radiation Therapy Radiation
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 29, 2018 (Actual)
- Primary completion
- May 10, 2022 (Actual)
- Completion
- May 10, 2022 (Actual)
- Last update posted
- Feb 20, 2024
2018 – 2022
United States locations
- U.S. sites
- 6
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| UCHealth University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| University of Kentucky/Markey Cancer Center | Lexington | Kentucky | 40536 | — |
| Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital | New Brunswick | New Jersey | 08903 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03345784, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 20, 2024 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03345784 live on ClinicalTrials.gov.